[Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia].

Related Articles

[Effect of metformin added to chemotherapy on the survival of patients with acute lymphoblastic leukemia].

Rev Med Chil. 2018 Jul;146(7):846-853

Authors: Ramos Peñafiel C, Olarte Carrillo I, Ceron Maldonado R, Miranda Peralta E, Rozen Fuller E, Kassack Ipiña JJ, Centeno Cruz F, Collazo Jaloma J, Martínez Tovar A

Abstract
BACKGROUND: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest.
AIM: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse.
MATERIAL AND METHODS: We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test.
RESULTS: The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006).
CONCLUSIONS: The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.

PMID: 30534883 [PubMed - in process]

from A via a.sfakia on Inoreader https://ift.tt/2SGXQVJ